OncoBeta Revenue
Medical Equipment Manufacturing • 
Garching, Bavaria, Germany • 21-50 Employees
OncoBeta revenue & valuation
| Annual revenue | $3,165,535 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $10,200,000 |
| Total funding | No funding |
Key Contacts at OncoBeta
Dr Sam Vohra
Global Scientific Director Advisory Position
Sasha Grubman
Medical Affairs Director- Global
Cody Allison
Ceo Medtech
Company overview
| Headquarters | Schleißheimer Straße 91, Garching, Bavaria 85748, DE |
| Phone number | +498932667330 |
| Website | |
| NAICS | 3391 |
| SIC | 384 |
| Keywords | Skin Cancer, Medical Device, Brachytherapy, Non-Melanoma Skin Cancer Treatment, Rhenium, Basal Cell Carcinoma, Squamous Cell Carcinoma, Radioisotope, Epidermal Radioisotope Therapy |
| Founded | 2011 |
| Employees | 21-50 |
| Socials |
OncoBeta Email Formats
OncoBeta uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@oncobeta.com), used 55% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@oncobeta.com | 70% |
{first initial}.{last name} | j.doe@oncobeta.com | 30% |
About OncoBeta
OncoBeta® GmbH located in Garching near Munich is a manufacturer and service provider of innovative medical solutions specialized in the development and commercialization of state-of-the-art therapies utilizing epidermal radioisotopes. We are very proud to be a pioneer and innovator in the epidermal radioisotope sector, presently offering a therapeutic application for physicians to treat non-melanoma skin cancer. Our current flag ship solution is the Rhenium-SCT® (Skin Cancer Therapy) a novel treatment option for basal cell carcinomas (BCCs) or squamous cell carcinomas (SCCs) based on the local irradiation of tumors with the beta-emitter Rhenium-188. Rhenium-188 is an optimal isotope for the treatment of superficial lesions such as non-melanoma skin cancers due to its practical penetration of 2-3mm in human tissue. Since the radioactive Rhenium does not come in direct contact with the patient, the Rhenium-SCT® is seen as a patient-personalised brachytherapy with minimal radiation exposition and adverse effects. The Rhenium-SCT is a CE certified method arising from over 10 years of experience and clinical studies (>700 patients, >1900 lesions). It provides non-melanoma skin cancer patients with a single-session, painless, highly-effective non- surgical treatment with excellent aesthetic results and complete remissions in up to 98,5% of all cases. We are also currently evaluating further exciting applications and treatment possibilities with rhenium-188.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
OncoBeta has 21 employees across 9 departments.
Departments
Number of employees
Funding Data
OncoBeta has never raised funding before.
OncoBeta Tech Stack
Discover the technologies and tools that power OncoBeta's digital infrastructure, from frameworks to analytics platforms.
Cookie compliance
JavaScript libraries
JavaScript libraries
Maps
JavaScript libraries
CDN
JavaScript libraries
Miscellaneous
JavaScript libraries
Programming languages
Analytics
United States
Egypt
France
Frequently asked questions
4.8
40,000 users
